Xtant Medical Holdings Inc Dossier
Qualitative Analysis
Business overview
Xtant Medical Holdings, Inc. (NYSE American: XTNT) is a vertically integrated medical technology company focused on the design, development, manufacture, and commercialization of regenerative biologics and spinal implant systems. The company's comprehensive product portfolio serves the specialized needs of orthopedic and neurological surgeons. Key offerings include orthobiologics such as demineralized bone matrix (DBM) allografts (e.g., OsteoSponge, OsteoSelect, and Trivium) and synthetic bone grafts (e.g., nanOss) to promote bone healing. Additionally, Xtant provides a wide range of spinal implants and instrumentation systems for complex spine, deformity, and degenerative procedures. Operating from its headquarters in Belgrade, Montana, Xtant is one of the few medical technology firms that controls its processing and manufacturing capabilities vertically, ensuring high standards of quality and safety.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Exiting the traditional spinal implant hardware market to focus resources and capital on the higher-margin orthobiologics and regenerative medicine business.
Expected impact: Improves gross margins, reduces operating expenses, and positions the company to achieve sustainable positive free cash flow.
Opportunistically adding to the field sales force and integrating specialized sales teams to improve market reach and leverage the company's contract portfolio.
Expected impact: Accelerates adoption of newly launched biologics and licensed products like HEMOBLAST Bellows.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides Xtant with exclusive U.S. commercial rights to HEMOBLAST Bellows for high-performance hemostasis, expanding its surgical portfolio and adding a 20-person specialized sales team.
Terms: Not fully disclosed; expected to contribute to the revised 2026 revenue guidance of $101 million to $105 million.
Acquired Xtant's non-core Coflex/CoFix assets and international hardware businesses, allowing Xtant to fully transition into a pure-play biologics company.
Terms: Total aggregate purchase price of $21.4 million, with the final $10.7 million payment received by Xtant on March 2, 2026.